Trastuzumab combined with irinotecan in patients with HER2-positive metastatic colorectal cancer: A phase II single-arm study and exploratory biomarker analysis.
A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer.
Nature Communications
Lee, Choong-Kun CK; Rha, Sun Young SY; Kim, Hyo Song HS; Jung, Minkyu M; Kang, Beodeul B; Che, Jingmin J; Kwon, Woo Sun WS; Park, Sejung S; Bae, Woo Kyun WK; Koo, Dong-Hoe DH; Shin, Su-Jin SJ; Kim, Hyunki H; Jeung, Hei-Cheul HC; Zang, Dae Young DY; Lee, Sang Kil SK; Nam, Chung Mo CM; Chung, Hyun Cheol HC
Improving prediction of response to neoadjuvant treatment in patients with breast cancer by combining liquid biopsies with multiparametric MRI: protocol of the LIMA study - a multicentre prospective observational cohort study.
Bmj Open
Janssen, Liselore M LM; Suelmann, Britt B M BBM; Elias, Sjoerd G SG; Janse, Markus H A MHA; van Diest, Paul J PJ; van der Wall, Elsken E; Gilhuijs, Kenneth G A KGA
Comprehensive genomic profiling of Finnish lung adenocarcinoma cohort reveals high clinical actionability and SMARCA4 altered tumors with variable histology and poor prognosis.
Neoplasia (New York, N.Y.)
Talvitie, Eva-Maria EM; Liljeroos, Lassi L; Vilhonen, Heikki H; Orte, Katri K; Leivo, Ilmo I; Kallajoki, Markku M; Taimen, Pekka P
Scalable multiplex co-fractionation/mass spectrometry platform for accelerated protein interactome discovery.
Nature Communications
Havugimana, Pierre C PC; Goel, Raghuveera Kumar RK; Phanse, Sadhna S; Youssef, Ahmed A; Padhorny, Dzmitry D; Kotelnikov, Sergei S; Kozakov, Dima D; Emili, Andrew A
Publication Date: 2022-07-13
Variant appearance in text: ERBB2: 2305G>C; Asp769His; rs121913468
Poziotinib Inhibits HER2-Mutant-Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer.
Cancer Research
Kalra, Rashi R; Chen, Ching Hui CH; Wang, Junkai J; Salam, Ahmad Bin AB; Dobrolecki, Lacey E LE; Lewis, Alaina A; Sallas, Christina C; Yates, Clayton C CC; Gutierrez, Carolina C; Karanam, Balasubramanyam B; Anurag, Meenakshi M; Lim, Bora B; Ellis, Matthew J MJ; Kavuri, Shyam M SM
Construction and validation of an immunoediting-based optimized neoantigen load (ioTNL) model to predict the response and prognosis of immune checkpoint therapy in various cancers.
Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients.
Evaluation of the Clinical Utility of Genomic Profiling to Inform Selection of Clinical Trial Therapy in Salivary Gland Cancer.
Cancers
Rack, Samuel S; Feeney, Laura L; Hapuarachi, Brindley B; Adderley, Helen H; Woodhouse, Laura L; Betts, Guy G; Burghel, George J GJ; Harrington, Kevin J KJ; Metcalf, Robert R
Targeted Therapy of Papillary Thyroid Cancer: A Comprehensive Genomic Analysis.
Frontiers In Endocrinology
Hescheler, Daniel A DA; Riemann, Burkhard B; Hartmann, Milan J M MJM; Michel, Maximilian M; Faust, Michael M; Bruns, Christiane J CJ; Alakus, Hakan H; Chiapponi, Costanza C
Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients.
Genome Medicine
Tsui, Dana W Y DWY; Cheng, Michael L ML; Shady, Maha M; Yang, Julie L JL; Stephens, Dennis D; Won, Helen H; Srinivasan, Preethi P; Huberman, Kety K; Meng, Fanli F; Jing, Xiaohong X; Patel, Juber J; Hasan, Maysun M; Johnson, Ian I; Gedvilaite, Erika E; Houck-Loomis, Brian B; Socci, Nicholas D ND; Selcuklu, S Duygu SD; Seshan, Venkatraman E VE; Zhang, Hongxin H; Chakravarty, Debyani D; Zehir, Ahmet A; Benayed, Ryma R; Arcila, Maria M; Ladanyi, Marc M; Funt, Samuel A SA; Feldman, Darren R DR; Li, Bob T BT; Razavi, Pedram P; Rosenberg, Jonathan J; Bajorin, Dean D; Iyer, Gopa G; Abida, Wassim W; Scher, Howard I HI; Rathkopf, Dana D; Viale, Agnes A; Berger, Michael F MF; Solit, David B DB
Genomic profile of advanced breast cancer in circulating tumour DNA.
Nature Communications
Kingston, Belinda B; Cutts, Rosalind J RJ; Bye, Hannah H; Beaney, Matthew M; Walsh-Crestani, Giselle G; Hrebien, Sarah S; Swift, Claire C; Kilburn, Lucy S LS; Kernaghan, Sarah S; Moretti, Laura L; Wilkinson, Katie K; Wardley, Andrew M AM; Macpherson, Iain R IR; Baird, Richard D RD; Roylance, Rebecca R; Reis-Filho, Jorge S JS; Hubank, Michael M; Faull, Iris I; Banks, Kimberly C KC; Lanman, Richard B RB; Garcia-Murillas, Isaac I; Bliss, Judith M JM; Ring, Alistair A; Turner, Nicholas C NC
Comprehensive omic characterization of breast cancer in Mexican-Hispanic women.
Nature Communications
Romero-Cordoba, Sandra L SL; Salido-Guadarrama, Ivan I; Rebollar-Vega, Rosa R; Bautista-Piña, Veronica V; Dominguez-Reyes, Carlos C; Tenorio-Torres, Alberto A; Villegas-Carlos, Felipe F; Fernández-López, Juan C JC; Uribe-Figueroa, Laura L; Alfaro-Ruiz, Luis L; Hidalgo-Miranda, Alfredo A
Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC).
Journal For Immunotherapy Of Cancer
Ricciuti, Biagio B; Jones, Greg G; Severgnini, Mariano M; Alessi, Joao V JV; Recondo, Gonzalo G; Lawrence, Marissa M; Forshew, Tim T; Lydon, Christine C; Nishino, Mizuki M; Cheng, Michael M; Awad, Mark M
Partial Response to Pyrotinib Plus Capecitabine in an Advanced Breast Cancer Patient with HER2 Amplification and R157W Mutation After Anti-HER2 Treatment: A Case Report and Literature Review.
Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer.
Cancer Medicine
Sivapiragasam, Abirami A; Ashok Kumar, Prashanth P; Sokol, Ethan S ES; Albacker, Lee A LA; Killian, Jonathan K JK; Ramkissoon, Shakti H SH; Huang, Richard S P RSP; Severson, Eric A EA; Brown, Charlotte A CA; Danziger, Natalie N; McGregor, Kimberly K; Ross, Jeffrey S JS
Distinct mutation profiles between primary bladder cancer and circulating tumor cells warrant the use of circulating tumors cells as cellular resource for mutation follow-up.
Bmc Cancer
Kim, Tae-Min TM; Yoo, Jin-Seon JS; Moon, Hyong Woo HW; Hur, Kyung Jae KJ; Choi, Jin Bong JB; Hong, Sung-Hoo SH; Lee, Ji Youl JY; Ha, U-Syn US
Esteban-Villarrubia, Jorge J; Soto-Castillo, Juan José JJ; Pozas, Javier J; San Román-Gil, María M; Orejana-Martín, Inmaculada I; Torres-Jiménez, Javier J; Carrato, Alfredo A; Alonso-Gordoa, Teresa T; Molina-Cerrillo, Javier J
Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials.
Jco Precision Oncology
Exman, Pedro P; Garrido-Castro, Ana C AC; Hughes, Melissa E ME; Freedman, Rachel A RA; Li, Tianyu T; Trippa, Lorenzo L; Bychkovsky, Brittany L BL; Barroso-Sousa, Romualdo R; Di Lascio, Simona S; Mackichan, Colin C; Lloyd, Max R MR; Krevalin, Max M; Cerami, Ethan E; Merrill, Margaret S MS; Santiago, Rebecca R; Crowley, Lindsey L; Kuhnly, Nicole N; Files, Janet J; Lindeman, Neal I NI; MacConaill, Laura E LE; Kumari, Priti P; Tolaney, Sara M SM; Krop, Ian E IE; Bose, Ron R; Johnson, Bruce E BE; Ma, Cynthia X CX; Dillon, Deborah A DA; Winer, Eric P EP; Wagle, Nikhil N; Lin, Nancy U NU
Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.
Breast Cancer Research : Bcr
Kurozumi, Sasagu S; Alsaleem, Mansour M; Monteiro, Cíntia J CJ; Bhardwaj, Kartikeya K; Joosten, Stacey E P SEP; Fujii, Takaaki T; Shirabe, Ken K; Green, Andrew R AR; Ellis, Ian O IO; Rakha, Emad A EA; Mongan, Nigel P NP; Heery, David M DM; Zwart, Wilbert W; Oesterreich, Steffi S; Johnston, Simon J SJ
Breast Cancer With a HER2 IHC2+ and FISH HER2/CEP17 Ratio ≥2.0 and an Average HER2 Gene Copy Number <4.0 per Tumor Cell: HER2 mRNA Overexpression Is a Rare Event.
Frontiers In Oncology
Liu, Yuanyuan Y; Wu, Shafei S; Shi, Xiaohua X; Mao, Feng F; Zeng, Xuan X
mTOR Signaling and SREBP Activity Increase FADS2 Expression and Can Activate Sapienate Biosynthesis.
Cell Reports
Triki, Mouna M; Rinaldi, Gianmarco G; Planque, Melanie M; Broekaert, Dorien D; Winkelkotte, Alina M AM; Maier, Carina R CR; Janaki Raman, Sudha S; Vandekeere, Anke A; Van Elsen, Joke J; Orth, Martin F MF; Grünewald, Thomas G P TGP; Schulze, Almut A; Fendt, Sarah-Maria SM
Phase and context shape the function of composite oncogenic mutations.
Nature
Gorelick, Alexander N AN; Sánchez-Rivera, Francisco J FJ; Cai, Yanyan Y; Bielski, Craig M CM; Biederstedt, Evan E; Jonsson, Philip P; Richards, Allison L AL; Vasan, Neil N; Penson, Alexander V AV; Friedman, Noah D ND; Ho, Yu-Jui YJ; Baslan, Timour T; Bandlamudi, Chaitanya C; Scaltriti, Maurizio M; Schultz, Nikolaus N; Lowe, Scott W SW; Reznik, Ed E; Taylor, Barry S BS